scholarly journals Analysis of existing international policy evidence in public health genomics: mapping exercise

2012 ◽  
Vol 1 (1) ◽  
pp. 8
Author(s):  
Elena V. Syurina ◽  
Tobias Schulte in den Bäumen ◽  
Frans J.M. Feron ◽  
Angela Brand
Keyword(s):  
Public Health ◽  
New Technologies ◽  
Human Subjects ◽  
Science Research ◽  
Institute Of Medicine ◽  
Public Health Genomics ◽  
The Public ◽  
Initial Stage ◽  
Protection Of Human Subjects ◽  
Design And Methods

<em>Background</em>. In the last decades we have seen a constant growth in the fields of science related to the use of genome-based health information. However, there is a gap between basic science research and the Public Health everyday practice. For a successful introduction of genome-based technologies policy actions on the international level are needed. This work represents the initial stage of the PHGEN II (Public Health Genomics European Network II) project. In order to prepare a base for bridging genomics and Public Health, an inventory study of the existing legislative base dealing with controversies of genome-based knowledge was conducted. The work results in the mapping of the most and the least legislatively covered areas and some preliminary conclusions about the existing gaps. <em>Design and Methods</em>. The collection of the evidence-based policies was done through the PHGEN II project. The mapping covered the meta-level (international, European general guidelines). The expert opinion of the partners of the project was required to reflect on and grade the collected evidence. Results. An analysis of the evidence was made by the area of coverage: using the list of important policy areas for successful introduction of genome-based technologies into Public Health and the Public Health Genomics Wheel (originally Public Health Wheel developed by Institute of Medicine). <em>Conclusions</em>. Severe inequalities in coverage of important issues of Public Health Genomics were found. The most attention was paid to clinical utility and clinical validity of the screening and the protection of human subjects. Important areas such as trade agreements, Public Health Genomics literacy, insurance issues, behaviour modification in response to genomics results etc. were paid less attention to. For the successful adoption of new technologies on the Public Health level the focus should be not only on the translation to clinical practice, but the translation from bench to Public Health policy and back. Coherent and consistent coverage of all aspects of the translation of genome based information and technologies is of outmost importance.

Zoom; or, Obsolescence

2021 ◽  
Vol 65 (3) ◽  
pp. 181-200
Author(s):  
W.B. Worthen
Keyword(s):  
Public Health ◽  
New Technologies ◽  
Virus Transmission ◽  
Electronic Media ◽  
Theatrical Production ◽  
Health Concerns ◽  
The Public

The signal modality of theatrical production during the pandemic crisis of 2020–21 has been Zoom theatre. While Zoom theatre responds to public health concerns regarding virus transmission, it also articulates a vision of performance at the intersection of the public and the private, at the juncture between theatre and electronic media, and as a representation of theatre as a humanizing technology. Theatre has suggestively foregrounded new technologies under the sign of obsolescence, and in the affective register of nostalgia.

Entering the Public Health Genomics Era

2007 ◽  
Vol 38 (3) ◽  
pp. 157-165 ◽  
Author(s):  
Lei-Shih Chen ◽  
Patricia Goodson
Keyword(s):  
Public Health ◽  
Public Health Genomics ◽  
The Public

scholarly journals Polygenic risk-stratified screening for cancer: Responsibilization in public health genomics

2019 ◽  
Vol 49 (4) ◽  
pp. 605-626 ◽  
Author(s):  
Anne Kerr ◽  
Tineke Broer ◽  
Emily Ross ◽  
Sarah Cunningham Burley
Keyword(s):  
Public Health ◽  
Research Participation ◽  
Molecular Data ◽  
Individual Risk ◽  
Personal Health ◽  
Public Health Genomics ◽  
Professional Discourse ◽  
Polygenic Risk ◽  
The Public ◽  
Data Practices

In this article, we examine professional discourse around the development of polygenic risk-stratified screening (PRSS) for cancer. Analyzing a range of contemporary professional literatures from Europe, North America and Australia, we explore how the drive to screen for molecular markers of cancer risk makes professionals, screening recipients and publics responsible, in different ways, for acquiring, curating and analyzing molecular data. Investigating how these responsibilities are invoked in discussions of new data practices, technologies, organizational arrangements, engagement, education and protocols for participation, we argue that agendas for PRSS for cancer are both expanding and stratifying responsibilities. Data collection is to be achieved by intensified responsibilities for including, reassuring and recruiting populations, as well as by opening and enriching the datasets on which models and preventative screening arrangements are based. Enhanced responsibilities for screening recipients and publics are also invoked, not just in relation to personal health but for population health more generally, via research participation and consenting to data re-use in the public interest. Professionals, screening recipients and publics are also to become responsible for moderating expectations of screening according to genomic designations. Together these discourses go beyond individual risk management to extend and diversify the responsibilities of practitioners, screening recipients and publics as public health genomics develops.

Biotechnology Venture Investing and Neurodegenerative Medicine: Promise of New Approaches to Cure an Ailing Model

2014 ◽  
Vol 20 (1) ◽  
Author(s):  
Dushon DeVere Riley ◽  
Mark Cochran
Keyword(s):  
Public Health ◽  
Venture Capital ◽  
Neurodegenerative Diseases ◽  
New Technologies ◽  
Genetic Knowledge ◽  
Venture Capitalists ◽  
Financial Model ◽  
The Public ◽  
Public Market ◽  
Public Health Challenges

Neurodegenerative diseases are one of the leading public health challenges of the next 50 years. Pharmaceutical therapies have traditionally targeted the later stages of neurodegenerative diseases; however, this strategy - as the recent failures of clinical trials for Alzheimer’s drugs have highlighted - has been unsuccessful. Venture capital has underperformed as well during this time, as many new companies have been unable to maintain growth once they reach the public market and have produced less than desirable returns. As a result, venture capitalists have opted for later-stage financing. Nevertheless, new technologies are being developed to answer the question of how to best address neurodegeneration. New tools of detection will allow for much earlier diagnosis and a much greater chance of discovering and applying effective treatments. Realizing that genetic knowledge is insufficient to produce innovative treatments for neurodegenerative diseases, scientists have begun to apply the genetic knowledge attained towards a future of individualized treatments. As these new tools of detection converge with an increased ability to create very precise individual solutions, the risk of successful future investments should come down and provide the potential for outsized returns that have traditionally governed the venture capital financial model.

scholarly journals Towards prevention of vitamin D deficiency and beyond: knowledge gaps and research needs in vitamin D nutrition and public health

2011 ◽  
Vol 106 (11) ◽  
pp. 1617-1627 ◽  
Author(s):  
Kevin D. Cashman ◽  
Mairead Kiely
Keyword(s):  
Public Health ◽  
Vitamin D ◽  
National Policy ◽  
Population Level ◽  
Institute Of Medicine ◽  
Knowledge Gaps ◽  
Public Health Perspective ◽  
The Public ◽  
Adverse Health Effects ◽  
The North

The North American Institute of Medicine (IOM) recently published their report on dietary reference intakes (DRI) for Ca and vitamin D. The DRI committee's deliberations underpinning this most comprehensive report on vitamin D nutrition to date benefited hugely from a much expanded knowledge base in vitamin D over the last decade or more. However, since their release, the vitamin D DRI have been the subject of intense controversy, which is largely due to the persistence of fundamental knowledge gaps in vitamin D. These can be identified at the levels of exposure, metabolism, storage, status, dose–response, function and beneficial or adverse health effects, as well as safe and effective application of intake recommendations at the population level through sustainable food-based approaches. The present review provides a brief overview of the approach used by the IOM committee to revise the DRI for vitamin D and to collate from a number of authoritative sources key knowledge gaps in vitamin D nutrition from the public health perspective. A number of research topics are outlined and data requirements within these are identified and mapped to the risk assessment framework used by the DRI committee. While not intended as an exhaustive list, it provides a basis for organising and prioritising research efforts in the area of vitamin D, which may offer a perspective on the major areas in need of attention. It is intended to be of use to researchers, national policy makers, the public health community, industry groups and other relevant stakeholders including funding institutions.

scholarly journals Potential Applications of Emerging Technologies in Disease Surveillance

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Jay Huang ◽  
Wayne Loschen
Keyword(s):  
Public Health ◽  
Health Professionals ◽  
Disease Surveillance ◽  
Public Health Surveillance ◽  
New Technologies ◽  
Emerging Technologies ◽  
Surveillance Systems ◽  
The Public ◽  
Public Health Professionals ◽  
Health Field

ObjectiveThe objective of this presentation is to explore emerging technologies and how they will impact the public health field. New technologies such as blockchain, artificial intelligence (AI), and the Internet of Things (IoT) will likely be incorporated into epidemiological methods and processes. This presentation will provide an overview of these technologies and focus on how they may impact public health surveillance in the future.IntroductionWith the increase in the amount of public health data along with the growth of public health informatics, it is important for epidemiologists to understand the current trends in technology and the impact they may have in the field. Because it is unfeasible for public health professionals to be an expert in every emerging technology, this presentation seeks to provide them with a better understanding of how emerging technologies may impact the field and the level of expertise required to realize benefits from the new technologies. Furthermore, understanding the capabilities provided by emerging technologies may guide future training and continuing education for public health professionals.MethodsAnalysis of current capabilities and potential advances in emerging technologies such as blockchain, AI, and IoT were performed by reviewing articles and whitepapers. In addition to a literature review, interviews will be performed with public health experts to determine how the emerging technologies align with current practices and the extent to which they may solve existing public health surveillance challenges.ResultsThe literature review revealed many emerging technologies and potential applications in the public health field, including:BlockchainBlockchains can serve as electronic health information exchanges that hold the metadata and access information for patient electronic health records (EHRs).1 These systems can ensure data privacy protections while also facilitate relevant data sharing from EHRs to disease surveillance systems. Furthermore, blockchain technology can be used in food supply chain management systems. During food contamination events, epidemiologists can trace through the blockchain to identify possible sources of the contamination.2AIAI can be used to improve the prediction and detection capabilities of disease surveillance systems. Machine learning algorithms can reveal patterns in the data and enable faster anomaly detection. Furthermore, machine learning models can be trained on data to create predictive models.IoTUrban IoT systems can monitor environmental indices including water and air quality, energy consumption, waste management, and traffic congestion in smart cities.3 The data collected from such systems can be incorporated into more comprehensive disease surveillance systems and assist epidemiologists in better understanding populations and environmental risk factors.We will analyze and discuss such prospective applications with public health professionals to determine their potential impact on public health processes and practices in the next one, five, and ten years.ConclusionsBlockchain, AI, IoT and other emerging technologies have applications in public health surveillance and impact the field to varying degrees. In addition to technological advances, there will be barriers to adoption that must be overcome before the value provided by the technologies can be realized. Many new technologies will require significant collaboration between public health departments, healthcare providers, and other partners to successfully incorporate the technologies into epidemiological processes. These collaborations include forming consortiums to exchange data in a blockchain and working with IoT providers for data access. Some technologies will require public health professionals to obtain additional training before they can take full advantage of the capabilities provided, while other technologies may be implemented by external partners allowing epidemiologists to utilize the new capabilities without the need to completely understand the underlying concepts. As emerging technologies are introduced into the public health field, a strong understanding of their capabilities and suitable applications will allow public health professionals to fully capture the benefits provided by the new technologies.References1. Ekblaw A, Azaria A, Halamka JD, Lippman A. A Case Study for Blockchain in Healthcare:“MedRec” prototype for electronic health records and medical research data. InProceedings of IEEE open & big data conference 2016 Aug 22 (Vol. 13, p. 13).2. Yiannas F. A New Era of Food Transparency Powered by Blockchain. Innovations: Technology, Governance, Globalization. 2018 Jul;12(1-2):46-56.3. Zanella A, Bui N, Castellani A, Vangelista L, Zorzi M. Internet of things for smart cities. IEEE Internet of Things Journal. 2014 Feb 14;1(1):22-32.

PP50 Microcosting With Time-Driven Activity-Based Costing Applied On Brazilian HTA System: ECMO Case Study

2018 ◽  
Vol 34 (S1) ◽  
pp. 85-86
Author(s):  
Ana Paula B S Etges ◽  
Priscila da Rosa ◽  
Regina K Notti ◽  
Luciane N Cruz ◽  
Madeni Doebber ◽  
...  
Keyword(s):  
Public Health ◽  
Health System ◽  
New Technologies ◽  
Public Health System ◽  
Critical Element ◽  
Activity Based Costing ◽  
The Real ◽  
The Public ◽  
Cardiorespiratory Failure ◽  
Implementation Costs

Introduction:Extracorporeal circulatory membrane oxygenation (ECMO) is a technology that allows recovery of adults in cardiorespiratory failure with encouraging results, but is not available in the Brazilian universal public health system (SUS) due to high implementation costs. Time-driven activity based costing (TDABC) is applied to measure processes in an economic perspective by identifying opportunities to make processes more efficient through the reduction of resources used in each activity. The literature has explored the use of TDABC to measure costs related with clinical procedures and technologies in microcosting studies, identifying opportunities to improve the process by making it more efficient. This research measures the real costs to implement ECMO in Brazil to compare with the current public reimbursement system.Methods:This study applied TDABC using data from 6 patients to measure costs of ECMO intervention considering the public perspective in Brazil. In sequence, standard price payed by SUS was used to estimate the current reimbursement amount received by the hospital for ECMO procedure. Cost variable analysis was conducted to understand when and how patients receiving ECMO are using hospital resources. Cost data were collected from an academic public hospital using an average of 18 months (2016–2017) for the department costs.Results:The real average cost was USD 128,923. Most significant resource costs was medical staff, particularly for the three survivor patients, and the ECMO equipment presented the second highest cost. ECMO activities were separated into: before implantation of ECMO, period using ECMO, intensive care post-ECMO and rehabilitation, being the period where ECMO is the most expensive, particularly in nurse and physician costs. The SUS average was USD 31,437, which shows a difference of USD 97,485 between the real ECMO cost and the public reimbursement in Brazil.Conclusions:A critical element of the propagation of ECMO in Brazil and its reimbursement by public health system is the high cost and out-of-date standard payments by the Ministry of Health. Effort to implement a trustworthy method to guide decisions of SUS for the adoption and financing new technologies is essential to contribute to the optimization of public health policies in a country with a universal health system and limited resources dedicated to health sectors.

Agents of Care

Germ Wars ◽  
2017 ◽  
Author(s):  
Melanie Armstrong
Keyword(s):  
Public Health ◽  
Homeland Security ◽  
Disease Surveillance ◽  
Health Agency ◽  
Science Research ◽  
Specific Work ◽  
Role Of Government ◽  
The Public ◽  
Political Transformations ◽  
Control And Prevention

Following 9/11 and the subsequent anthrax attacks, the U.S. government enlisted the public health industry in homeland security and defense, bringing weapons like disease surveillance and life science research to the war against terrorism. As Congress poured out funding for bioterrorism preparedness, agencies like the Centers for Disease Control and Prevention rearranged themselves around new logics of biosecurity. In the decade after 9/11, CDC brought its surveillance, science, and communication practices to bear on questions of national security, and became a federal organizing agency for emergency response and pharmaceutical stockpile stewardship. The political transformations at the CDC exemplify how bioterrorism changed the role of government in disease management, along with the specific work of the nation’s largest public health agency.

Sign in / Sign up

Export Citation Format

Share Document